| |
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility.
|
|
Today’s Big NewsNov 27, 2023 |
|
With Cytiva™️ Protein Select™️ resin, you will finally be able to standardize recombinant protein purification with a platform process. Request information.
|
|
| By Andrea Park In many ways, 2023 has been a banner year for women, thanks to Barbie, Beyoncé, Taylor Swift and so many other female powerhouses the world over. |
|
|
|
By Max Bayer CRISPR Therapeutics laid off some of its staffers a week after FDA advisers endorsed the company's Vertex-sponsored, gene-edited cell therapy, according to the three sources. The company reported having more than $1.7 billion in cash as of the end of September. |
By Annalee Armstrong Roivant’s CEO Matt Gline always knew the lupus drug brepocitinib was a longshot: “Anybody who is not afraid of a lupus study is an idiot, you shouldn’t trust them,” he told Fierce Biotech at the beginning of the year. Now, it seems Gline’s fear was warranted. |
Sponsored by WCG Pediatric CGT trials have the potential to cure diseases and prolong lives. Discover steps to protect safety and enhance operations in your CGT trials. |
By Nick Paul Taylor GSK has jilted Sosei Heptares on the cusp of the clinic. With approval to start first-in-human studies in place, the Big Pharma has backed out of the program, reportedly because of changes at its immunology unit, and returned full rights to an inflammatory bowel disease asset Sosei sees as a potential blockbuster. |
By Nick Paul Taylor AstraZeneca’s business development team has landed another asset in its new favorite hunting grounds. Partnering with a Chinese biotech once again, the Anglo-Swedish drugmaker has secured a spot in the congested KRAS G12D space in exchange for $24 million upfront. |
By James Waldron It’s been a wild November for Theseus Pharmaceuticals. Just a couple of weeks ago, the biotech laid off almost three-quarters of its staff. Days later, the company received offers from two sets of potential buyers. |
By Max Bayer Xenon hopes to expand its lead asset's use beyond epilepsy, but phase 2 data in patients with major depressive disorder has missed the mark. |
By Helen Floersh On the heels of a major publication from the COVID-19 Moonshot project, an open science initiative involving hundreds of scientists from around the world who sought to develop new COVID antivirals, Fierce spoke with leaders Alpha Lee and Annette von Delft to chat about the program's challenges, successes and learnings that can be applied to drug discovery more broadly. |
By Fraiser Kansteiner After plotting $6 billion in production upgrades earlier this month, Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggested the expansion outlay was just the start. Now, some three weeks later, he’s putting his company’s money where his mouth is. |
By Andrea Park For the second time this month, Roche is launching a new immunoassay to help diagnose cases of hepatitis. |
By Zoey Becker Pfizer's commercial office in Citywest, Dublin, will move to its Ringsend office building, the Irish Independent reports. The moves could end in more job cuts in the company's commercial division. |
By Dave Muoio The nation's largest MA operator is skirting new CMS regulations prohibiting MA plans from limiting or denying coverage for hospital services that would be covered under traditional Medicare, the hospital industry told federal officials this week. |
By Ben Adams NS Pharma is launching a new educational campaign for Duchenne Muscular Dystrophy (DMD) aimed at assisting families with DMD patients in navigating both the emotional and medical aspects of their journey. |
Fierce podcastsDon’t miss an episode |
| This episode of "The Top Line" is dedicated to Alzheimer’s disease, spotlighting the latest treatments and what lies ahead. Fierce Pharma's Fraiser Kansteiner discusses Leqembi's full approval with Eisai's Alexander Scott. Annalee Armstrong from Fierce Biotech interviews Alzheimer's expert Howard Fillit, M.D., exploring groundbreaking research. Fierce Pharma’s Eric Sagonowsky speaks with Reisa Sperling, M.D., about Leqembi's potential in preventing Alzheimer’s progression before symptoms emerge. |
|
|---|
|
|
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
